New hope for kidney patients: experimental drug targets protein leak

NCT ID NCT05267262

Completed Disease control Sponsor: River 3 Renal Corp. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called R3R01 in 43 people with two rare kidney diseases (Alport syndrome and focal segmental glomerulosclerosis) whose protein in urine remained high despite standard treatment. The main goals were to check safety and see if the drug could reduce protein leakage from the kidneys. Results will help decide if larger studies are warranted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alport syndrome focal segmental glomerulosclerosis hereditary nephritis kidney disorder primary focal segmental glomerulosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALPORT SYNDROME FOCAL SEGMENTAL GLOMERULOSCLEROSIS

Contacts and locations

Locations

Investigative Site

Los Angeles, California, 90022, United States
Investigative Site

Cary, North Carolina, 27511, United States
Investigative Site

Dallas, Texas, 75204, United States
Investigative site

Boca Raton, Florida, 33431, United States
Investigative site

Miami, Florida, 33136, United States
Investigative site

Riverview, Florida, 33578, United States
Investigative site

Atlanta, Georgia, 30322, United States
Investigative site

Boston, Massachusetts, 02111, United States
Investigative site

Ann Arbor, Michigan, 48109-5718, United States
Investigative site

Minneapolis, Minnesota, 55454, United States
Investigative site

Cleveland, Ohio, 44195, United States
Investigative site

Columbus, Ohio, 43235, United States
Investigative site

East Providence, Rhode Island, 02914, United States
Investigative site

Houston, Texas, 77054, United States
Investigative site

Brussels, 1200, Belgium
Investigative site

Liège, 4000, Belgium
Investigative site

Paris, 75015, France
Investigative site

Göttingen, 37075, Germany
Investigative site

Amsterdam, 1105AZ, Netherlands
Investigative site

Nijmegen, 6525 GA, Netherlands
Investigative site

Leicester, LE5 4PW, United Kingdom
Investigative site

Nottingham, NG5 1PB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.